Drug Trial Radar · NCT04089566
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Last checked: Nov 20, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Mar 26, 2020
Primary completion
Feb 21, 2024
Study completion May 30, 2024
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Sep 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 7 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children's Hospital of Philadelphia-Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score (Part B); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C). The secondary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A, B and C); to examine the effect of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA, to examine the effect of nusinersen administered intrathecally at higher doses compared to the currently approved dose in participants with SMA (Part B).
Conditions
- Muscular Atrophy, Spinal
Interventions
NusinersenDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part B Infantile-onset SMA: Change From Baseline in CHOP-INTEND Total Score for 50/28mg Nusinersen Versus CS3B Matched Sham Control GroupTime frame: Baseline, Day 183
- Parts A and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)Time frame: Part A: From the first dose of the study drug up to Day 389, Part C: From the first dose of the study drug up to Day 361
- Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)Time frame: Parts A and C: Baseline up to Day 302
- Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Hematology Parameters)Time frame: Parts A and C: Baseline up to Day 302
- Parts A and C: Number of Participants With Shifts From Baseline in UrinalysisTime frame: Parts A and C: Baseline up to Day 302
- Parts A and C: Number of Participants With Shifts From Baseline in Cerebrospinal Fluid (CSF) ParametersTime frame: Part A: Baseline up to Day 269, Part C: Baseline up to Day 241
- Parts A and C: Number of Participants With Shifts From Baseline in Electrocardiograms (ECGs)Time frame: Parts A and C: Baseline up to Day 302
- Parts A and C: Number of Participants With Abnormalities in Vital Sign ParametersTime frame: Parts A and C: Baseline up to Day 302
- Parts A and C: Change From Baseline in Growth Parameters (Body Height)Time frame: Parts A and C: Baseline, Day 302
- Part C: Change From Baseline in Growth Parameters (Head Circumference)Time frame: Baseline, Day 302
- Part C: Change From Baseline in Growth Parameters (Chest Circumference)Time frame: Baseline, Day 302
- Part C: Change From Baseline in Growth Parameters (Arm Circumference)Time frame: Baseline, Day 302
- Parts A and C: Change From Baseline in Growth Parameters (Ulnar Length)Time frame: Parts A and C: Baseline, Day 302
- Parts A and C: Change From Baseline in Growth Parameters (Weight for Age Percentile)Time frame: Parts A and C: Baseline, Day 302
- Part C: Change From Baseline in Growth Parameters (Weight for Length Ratio)Time frame: Baseline, Day 302
- Part C: Change From Baseline in Growth Parameters (Head-to-Chest Circumference Ratio)Time frame: Baseline, Day 302
- Parts A and C: Number of Participants With Shifts From Baseline in Coagulation Parameters (Activated Partial Thromboplastin Time (aPTT))Time frame: Parts A and C: Baseline up to Day 269
- Parts A and C: Number of Participants With Shifts From Baseline in Coagulation Parameters (Prothrombin Time (PT))Time frame: Parts A and C: Baseline up to Day 269
- Parts A and C: Number of Participants With Shifts From Baseline in Coagulation Parameters (International Normalized Ratio (INR))Time frame: Parts A and C: Baseline up to Day 269
- Parts A and C: Change From Baseline in Urine Total ProteinTime frame: Parts A and C: Baseline, Day 302
- Parts A and C: Number of Participants With Neurological Examination Abnormalities Reported as AEsTime frame: Parts A and C: Baseline up to Day 302
- Parts A and C: Percentage of Participants With a Postbaseline Platelet Count Below the Lower Limit of Normal on at Least 2 Consecutive MeasurementsTime frame: Parts A and C: Baseline up to Day 302
- Parts A and C: Percentage of Participants With a Postbaseline Corrected QT Interval Using Fridericia's Formula (QTcF) of > 500 Millisecond (Msec) and an Increase From Baseline to Any Postbaseline Timepoint in QTcF of > 60 MsecTime frame: Parts A and C: Baseline up to Day 302
Locations
45 sites in 18 countries. Site status is shown where the registry gives one.
Stanford Hospital and Clinics
Palo Alto, California
Children's Hospital Colorado
Aurora, Colorado
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
The Johns Hopkins Hospital
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
St. Jude Children's Research Hospital
Memphis, Tennessee
The University of Texas Southwestern Medical Center
Dallas, Texas
HC-UFMG - Hospital das Clinicas da Universidade Federal de Minas Gerais
Belo Horizonte, Minas Gerais, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, São Paulo, Brazil
London Health Sciences Centre (LHSC) - Children's Hospital
London, Ontario, Canada
Hospital Luis Calvo Mackenna
Santiago, Chile
Clinica Las Condes
Santiago, Chile
Clinica MEDS La Dehesa
Santiago, Chile
Peking University First Hospital
Beijing, Beijing Municipality, China
The Children's Hospital of Zhejiang University school of Med_Hangzhou
Hangzhou, Binjiang, China
Guangzhou Woman and Children's Medical Center
Guangzhou, Guangzhou, China
Xiangya Hospital, Central South University
Changsha, Hu'nan, China
Hospital Universitario San Ignacio
Bogotá, Colombia
Fundacion Hospitalaria San Vicente de Paul
Medellín, Colombia
Tallinn Children's Hospital
Tallinn, Estonia
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Universitaetsklinikum Giessen und Marburg GmbH
Giessen, Hesse, Germany
Semmelweis Egyetem
Budapest, Hungary
Magyarorszagi Reformatus Egyhaz Bethesda Gyermekkorhaz
Budapest, Hungary
Fondazione Serena Onlus - Centro Clinico Nemo
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
Kurume University Hospital
Kurume-shi, Fukuoka, Japan
Hyogo College of Medicine Hospital
Nishinomiya-shi, Hyōgo, Japan
Tokyo Women's Medical University Hospital
Shinjuku-ku, Tokyo-To, Japan
Saint George University Hospital Medical Center
Beirut, Lebanon
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, Jalisco, Mexico
Instituto Nacional de Pediatria
Mexico City, Mexico City, Mexico
Hospital Infantil de Mexico Federico Gomez
Mexico City, Mexico City, Mexico
Instytut Pomnik - Centrum Zdrowia Dziecka
Warsaw, Poland
Russian Children Neuromuscular Center of Veltischev
Moskva, Russia
Regional Pediatric Clinical Hospital #1
Yekaterinburg, Russia
King Fahad Specialist Hospital
Dammam, Saudi Arabia
National Guard Health Affairs: King Abdulaziz Medical City
Jeddah, Saudi Arabia
King Faisal Specialist Hospital & Research Center
Riyadh, Saudi Arabia
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.